Administering the G-200 Vaccine
Andrew T. Parsa MD, PhD, from the University of California, San Francisco, describes the administration of the prophage G-200 for recurrent glioblastoma multiforme.
Andrew T. Parsa MD, PhD, Associate Professor in Residence of Neurological Surgery, University of California, San Francisco, describes the administration of the prophage G-200 for recurrent glioblastoma multiforme.
A patient does not have to go through leukapheresis, nor receive additional cytokines such as GM-CSF, a common approach for many types of vaccines for brain tumor patients. As a part of standard of care, a patient undergoes surgical resection. That resected tissue is used to make the vaccine. In a majority of cases, patients who have a recurrent glioblastoma can have the vaccine made from surgical resection without an issue.
Clinical Pearls
A physician will administer as many doses as a patient can tolerate with regard to the amount of vaccine, up to six, Parsa says.
- The patient does not have to go through leukapheresis, nor receive additional cytokines
- Resected tissue is used to make the vaccine
- The patient will receive as many doses as he/she is able to tolerate
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
December 10th 2024In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
